Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H27NO2 |
Molecular Weight | 361.4767 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=FMJSMJQBSVNSBF-UHFFFAOYSA-N
InChI=1S/C24H27NO2/c1-3-5-12-19(4-2)18-27-24(26)22(17-25)23(20-13-8-6-9-14-20)21-15-10-7-11-16-21/h6-11,13-16,19H,3-5,12,18H2,1-2H3
DescriptionSources: http://www.thedermreview.com/octocrylene/Curator's Comment: description was created based on several sources, including, http://onlinelibrary.wiley.com/doi/10.1111/cod.12205/epdf
Sources: http://www.thedermreview.com/octocrylene/
Curator's Comment: description was created based on several sources, including, http://onlinelibrary.wiley.com/doi/10.1111/cod.12205/epdf
Octocrylene is a compound often used as an additive in sun screen, and is thought to have skin moisturizing effects because of its emollient properties. What makes this chemical such a popular additive to sun block, is its ability to neutralize UV radiation dissipated by sunlight, and to minimize skin damage from prolonged sun exposure. Octocrylene is also often combined with avobenzone, another common sunscreen ingredient often appearing on ingredient labels. Because of its effectiveness, the chemical has been approved across the globe for use in cosmetics and skin care products, but the concentrations of this ingredient are usually limited to no more than 10 or 12 percent. However, the use of this chemical doesn’t just stop with sunscreen for face and arms, but can extend to a variety of other products, like hair spray, tannin oil, BB cream, conditioner, and CC cream, among others. Octocrylene may cause contact and photocontact allergy.
Originator
Sources: http://www.google.com/patents/US7037511
Curator's Comment: http://143230426296262911.weebly.com/introduction-to-molecule.html
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.7 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31058986 |
2.7 g single, topical dose: 2.7 g route of administration: Topical experiment type: SINGLE co-administered: |
OCTOCRYLENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31058986 |
2.7 g 4 times / day steady-state, topical dose: 2.7 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
OCTOCRYLENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
43.3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31058986 |
2.7 g 4 times / day steady-state, topical dose: 2.7 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
OCTOCRYLENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.7 g 1.3 times / day multiple, topical (median) Recommended Dose: 3.7 g, 1.3 times / day Route: topical Route: multiple Dose: 3.7 g, 1.3 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 3.69 years (range: 0.64-48.15 years) n = 79 Health Status: healthy Age Group: 3.69 years (range: 0.64-48.15 years) Sex: M+F Population Size: 79 Sources: |
Other AEs: Dermatitis, Eczema... |
1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Other AEs: Acne, Dermatitis... Other AEs: Acne (4.8%) Sources: Dermatitis (2.8%) Dry skin (1.2%) Eczema (1.2%) Erythema (1.2%) Pruritus (2%) Rosacea (0.4%) Seborrhea (0.8%) Skin discomfort (1.2%) Sunburn (0.8%) Conjunctivitis (0.8%) Taste perversion (0.4%) |
3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Other AEs: Dermatitis, Eczema... Other AEs: Dermatitis (2.8%) Sources: Eczema (0.4%) Erythema (0.8%) Skin discomfort (0.8%) Sunburn (1.6%) Conjunctivitis (0.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Eczema | 1.3% | 3.7 g 1.3 times / day multiple, topical (median) Recommended Dose: 3.7 g, 1.3 times / day Route: topical Route: multiple Dose: 3.7 g, 1.3 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 3.69 years (range: 0.64-48.15 years) n = 79 Health Status: healthy Age Group: 3.69 years (range: 0.64-48.15 years) Sex: M+F Population Size: 79 Sources: |
Dermatitis | 2.5% | 3.7 g 1.3 times / day multiple, topical (median) Recommended Dose: 3.7 g, 1.3 times / day Route: topical Route: multiple Dose: 3.7 g, 1.3 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 3.69 years (range: 0.64-48.15 years) n = 79 Health Status: healthy Age Group: 3.69 years (range: 0.64-48.15 years) Sex: M+F Population Size: 79 Sources: |
Rosacea | 0.4% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Taste perversion | 0.4% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Conjunctivitis | 0.8% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Seborrhea | 0.8% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Sunburn | 0.8% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Dry skin | 1.2% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Eczema | 1.2% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Erythema | 1.2% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Skin discomfort | 1.2% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Pruritus | 2% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Dermatitis | 2.8% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Acne | 4.8% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Conjunctivitis | 0.4% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Eczema | 0.4% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Erythema | 0.8% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Skin discomfort | 0.8% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Sunburn | 1.6% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Dermatitis | 2.8% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: avobenzone titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/28704989/ |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Sunscreen penetration of human skin and related keratinocyte toxicity after topical application. | 2005 Jul-Aug |
|
Assay of common sunscreen agents in suncare products by high-performance liquid chromatography on a cyanopropyl-bonded silica column. | 2005 Jun 15 |
|
Sunscreens - which and what for? | 2005 Nov-Dec |
|
Concentrations and specific loads of UV filters in sewage sludge originating from a monitoring network in Switzerland. | 2006 Feb |
|
Incorporation in lipid microparticles of the UVA filter, butyl methoxydibenzoylmethane combined with the UVB filter, octocrylene: effect on photostability. | 2009 |
|
Determination of personal care products in sewage sludge by pressurized liquid extraction and ultra high performance liquid chromatography-tandem mass spectrometry. | 2009 Jul 24 |
|
Determination of selected UV filters in indoor dust by matrix solid-phase dispersion and gas chromatography-tandem mass spectrometry. | 2009 Jul 31 |
|
Irradiation of skin and contrasting effects on absorption of hydrophilic and lipophilic compounds. | 2009 Nov-Dec |
Sample Use Guides
The study was performed in vitro using a Franz type diffusion cell. Only one of the products contained octocrylene and the concentration was 70 g/L (~7%). The sunscreen product was applied to human skin (surface area = 1.13 -1.23 cm2). Following 8-hr topical applications of the products it was reported that no octocrylene was detected in the receptor fluid suggesting that penetration through the skin was minimal to non-existent.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 217
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
||
|
CFR |
21 CFR 352.10
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
||
|
NCI_THESAURUS |
C851
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
||
|
CFR |
21 CFR 352.20
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
228-250-8
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
1477411
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
3395
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
m8115
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
4719
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
C088673
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
22571
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
C84027
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
6197-30-4
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
OCTOCRYLENE
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
SUB09413MIG
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
760433
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
DTXSID9025299
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
100000083846
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
5A68WGF6WM
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201147
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
77674
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
5A68WGF6WM
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY | |||
|
DB09535
Created by
admin on Fri Dec 15 15:26:19 GMT 2023 , Edited by admin on Fri Dec 15 15:26:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY